Bronchial artery embolization for malignant XXXX : a single institutional experience.

@entity1 @entity882 @entity1416 @entity887 @entity358 @entity3 @entity5492
OBJECTIVE: To assess the effectiveness of @entity1416 ( @entity1416 ) in @entity1 with malignant @entity5492 . METHODS: An IRB-approved retrospective study at our academic institution was conducted on all @entity1 treated by @entity1416 for @entity5492 from @entity358 . Outcome and safety measures were documented according to Society of Interventional Radiology (SIR) practice guidelines. RESULTS: A total of 26 @entity1 (13 male, 13 female) with @entity358 underwent @entity1416 for @entity5492 from 2003-2013. Histologic analysis revealed 80% (21/26) of cases were from primary @entity358 , while the remaining 20% (4/26) represented @entity3 . Sixty-five percent (17/26) of @entity1 underwent bronchoscopy prior to @entity1416 . Follow-up ranged from 2 to 1,909 days, with average of 155 days. Technical success was achieved in 77% of @entity1 (20/26). Clinical success rate was 75% (15/20). Eighty-five percent of embolized @entity1 (17/20) were treated with particles, 15% (3/20) with gelfoam, and 20% (4/20) with coils. @entity887 was performed in 70% (14/20), two-vessel in 20% (4/20), and multiple vessels in 10% (2/20). No complications were reported. Six-month all-cause mortality of treated cases was 55% (11/20) with an in-hospital mortality of 25% (5/20). Ten percent (2/20) had remote re-bleeding events beyond 6 months. Statistically significant predictors of mortality were intubation status, hemoglobin/hematocrit at presentation, and @entity882 . CONCLUSIONS: @entity1416 is a safe and useful treatment for clinically significant @entity5492 in @entity1 with primary or metastatic lung masses despite high overall mortality. Intubation status, low hemoglobin/hematocrit, and @entity882 may represent clinical predictors of short term mortality following @entity1416 . ADVANCES IN KNOWLEDGE: Most @entity1 undergoing @entity1416 for malignant @entity5492 achieve high clinical success despite suffering a high mortality from underlying disease.
